Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx N.V. (Nasdaq: IFRX) announced that all their submitted abstracts featuring vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) have been accepted for presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FL.
The presentations include first-time data on reduction in draining tunnels with vilobelimab in HS patients, and insights on a modified HiSCR scoring system. The abstracts cover safety studies, pharmacokinetic/pharmacodynamic analyses, and efficacy data from Phase 2 trials in both PG and HS conditions.
Vilobelimab, a first-in-class monoclonal anti-human complement factor C5a antibody, is currently in Phase 3 trials for PG and has received orphan drug designation from both FDA and EMA, plus FDA fast track designation for PG treatment.
InflaRx (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, will release its fourth quarter and full year 2024 financial results on March 20, 2025, without a conference call.
The company will participate in two upcoming investor conferences: the Leerink Global Healthcare Conference (March 9-12 in Miami Beach) featuring a fireside chat on March 10 at 10:40 AM ET, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, with a virtual fireside chat at 8:30 AM ET. Both events will include one-on-one investor meetings.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate is vilobelimab, an intravenous anti-C5a monoclonal antibody, and they're also developing INF904, an oral C5a receptor inhibitor.
InflaRx (Nasdaq: IFRX) has completed its underwritten public offering, raising approximately $30 million in gross proceeds. The offering consisted of 8,250,000 ordinary shares priced at $2.00 per share and pre-funded warrants to purchase up to 6,750,000 ordinary shares. The pre-funded warrants were priced at $1.999 each, with an exercise price of $0.001.
The company has granted underwriters a 30-day option to purchase up to 2,250,000 additional ordinary shares. The net proceeds will be used to fund clinical development of pipeline candidates, including vilobelimab and INF904, and for general corporate purposes. Guggenheim Securities acted as book-running manager, with H.C. Wainwright & Co. and Lucid Capital Markets as co-lead managers.
Infinitum has launched a new blockchain ecosystem designed to bridge traditional finance (TradFi) and decentralized finance (DeFi). The platform, developed in partnership with financial systems leader Lusis, focuses on post-quantum security and asset tokenization.
According to a 2023 Bank of America report, asset tokenization is expected to represent 10% of global GDP by 2030. The ecosystem addresses critical challenges in modern finance, including scalability, regulatory compliance, and security concerns related to quantum computing advancements.
The project features Infinitum Labs, a dedicated research hub co-founded with Lusis, leveraging expertise in financial systems, cryptography, AI integration, and quantum computing. The platform implements post-quantum resilient systems and AI-driven fraud prevention to protect digital assets from potential quantum computing threats.
InflaRx N.V. (IFRX) has announced the pricing of its public offering, consisting of 8,250,000 ordinary shares at $2.00 per share and pre-funded warrants to purchase up to 6,750,000 ordinary shares. The pre-funded warrants are priced at $1.999 each, with a $0.001 exercise price.
The offering, expected to close on February 18, 2025, includes a 30-day option for underwriters to purchase up to 2,250,000 additional ordinary shares. Guggenheim Securities is serving as the book-running manager, with H.C. Wainwright & Co. and Lucid Capital Markets as co-lead managers.
The company plans to use the proceeds to fund clinical development of its pipeline candidates, including vilobelimab and INF904, and for general corporate purposes.
InflaRx N.V. (IFRX) has announced the commencement of an underwritten public offering of ordinary shares and pre-funded warrants. The pre-funded warrants will be priced at the public offering price minus $0.001, which will be their exercise price. Guggenheim Securities, is serving as the book-running manager for the offering.
The company plans to grant underwriters a 30-day option to purchase additional ordinary shares at the public offering price, less underwriting discount. The net proceeds will be used to fund clinical development of pipeline candidates, including vilobelimab and INF904, and for general corporate purposes.
The offering is being made under a shelf registration statement declared effective by the SEC on July 11, 2023. The final terms will be disclosed in a final prospectus supplement to be filed with the SEC.
InflaRx N.V. (IFRX) has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York. The company specializes in developing anti-inflammatory therapeutics targeting the complement system.
InflaRx's primary focus is on their proprietary anti-C5a and anti-C5aR technologies, which are used to develop inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate, vilobelimab, is an intravenous first-in-class anti-C5a monoclonal antibody that has shown promising clinical activity across multiple indications. The company is also developing INF904, an oral small molecule C5a receptor inhibitor.
InflaRx (NASDAQ: IFRX) has received European Commission marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab), the first approved treatment in the European Union for SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). The approval applies to adult patients receiving systemic corticosteroids and invasive mechanical ventilation, with or without ECMO.
The authorization is supported by Phase 3 PANAMO trial results, which demonstrated a 23.9% relative reduction in 28-day all-cause mortality compared to placebo. The approval covers all 27 EU member states plus Iceland, Liechtenstein, and Norway. InflaRx is exploring commercial partnering options in the EU.
In the US, GOHIBIC has received Emergency Use Authorization from the FDA for COVID-19 treatment in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or ECMO.
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in multiple events during the week of January 13, 2025, in San Francisco. The company will attend the LifeSci Partners Corporate Access Event for one-on-one meetings on January 14-15, and participate in a workshop at Biotech Showcase 2025 on January 15 titled 'The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World.'
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate, vilobelimab, is an intravenous anti-C5a monoclonal antibody. The company is also developing INF904, an oral C5a receptor inhibitor. Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.
InflaRx has initiated dosing in its Phase 2a basket study for INF904, an oral C5aR inhibitor, targeting chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS). The study will enroll 75 patients, with 45 CSU patients receiving doses of 60mg or 120mg BID, and 30 HS patients randomized across 60mg, 90mg, or 120mg BID doses over 4 weeks. The trial aims to evaluate safety, pharmacokinetics, and clinical benefits, with data expected in summer 2025. Each indication represents potential addressable markets of $1 billion or more. The company plans to use study results to design a larger Phase 2b trial by year-end 2025.